COURSE DESCRIPTION

This one-day symposium will provide a comprehensive update on advances in the management of patients with lung cancer. Lung cancer is the leading cause of cancer-related deaths in the United States, with over 225,000 people being diagnosed last year. Recommendations for CT screening in lung cancer have been updated, newer diagnostic and local treatment modalities are available, significant advances have been made in immunotherapeutic approaches, and exciting new agents are being developed in EGFR-mutant and ALK-rearranged lung cancer. This symposium will review all of the recent advances in a highly interactive case-based discussion format, supported by didactic lectures by thought leaders and other well-respected faculty in each field.

LEARNING OBJECTIVES

• Utilize current USPTF/ACS guidelines for appropriate screening for lung cancer in high risk individuals with an emphasis on smoking cessation

• Apply ASTRO/IASLC guidelines to select appropriate patients for treatment with stereotactic radiosurgical techniques or proton beam therapy

• Apply the 7th edition of the AJCC staging system and utilize appropriate staging modalities to arrive at the correct stage

• Review radiation therapy options, recommend the appropriate radiation treatment method(s) and educate patients accordingly.

• Review controversial issues surrounding the role of surgery such as in small cell lung cancer, N2 node-positive non-small cell lung cancer, or sub-lobar resections and perform appropriate patient selection for the right procedure for optimal oncologic outcomes

• Explain the initial immunotherapy clinical trial data in non-small cell lung cancer, learn to recognize the response profile and side effects of these medications and manage immune-mediated complications

• Analyze malignant tumors genomically with novel technologies such as liquid biopsies and select therapies using a targeted approach when clinical trial data indicate efficacy, with focus on newer EGFR and ALK inhibitors

• Elucidate on the management of patients with NSCLC tumors harboring rare mutations and with brain or leptomeningeal metastases

TARGET AUDIENCE

This conference is intended for pulmonologists, medical and radiation oncologists, thoracic surgeons, interventional radiologists, oncology nurses, radiation therapy technologists, advanced practice clinicians, residents and fellows.

CME ACCREDITATION

MedStar Georgetown University Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

MedStar Georgetown University Hospital designates this live activity for a maximum of 6.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Directors:Deepa S. Subramaniam, MD, MScGeorgetown Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalWashington, DC

Giuseppe Giaccone, MD, PhDMedStar Georgetown Cancer NetworkGeorgetown Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalWashington, DC

LUNG CANCER 2016:November 12, 2016 | Capital Hilton | Washington, DC

Progress and Future Directions

CME Information

For more information and to register, please visit http://cme.medstarwashington.org/LungCancer

MedStar Health / SiTEL3007 Tilden Ave, NWSuite 3NWashington, DC 20008

LUNG CANCER 2016:November 12, 2016 | Capital Hilton | Washington, DC

Progress and Future Directions

COURSE DIRECTORS

Deepa S. Subramaniam, MD, MSc Director, Multidisciplinary Thoracic Oncology ClinicFull Member, Clinical & Experimental Therapeutics ProgramGeorgetown Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalWashington, DC

Giuseppe Giaccone, MD, PhD Director, Clinical ResearchMedStar Georgetown Cancer NetworkAssociate Director, Clinical ResearchGeorgetown Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalWashington, DC

FACULTY

Eric D. Anderson, MD Director, Interventional PulmonologyMedStar Georgetown University HospitalWashington, DC

Mark M. Awad, MD, PhD Thoracic OncologistDana-Farber Cancer InstituteInstructor in MedicineHarvard Medical SchoolBoston, MA

Geoffrey T. Gibney, MD Co-Leader, Melanoma Disease GroupGeorgetown Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalWashington, DC

Russell K. Hales, MD Director, Thoracic Oncology Multidisciplinary ClinicJohns Hopkins MedicineAssistant Professor, Radiation Oncology and Molecular Radiation SciencesJohns Hopkins UniversityBaltimore, MD

Claudia I. Henschke, MD, PhD Director, Early Lung and Cardiac Action ProgramMount Sinai HospitalProfessor of RadiologyThe Mount Sinai Health SystemNew York, NY

Stephen V. Liu, MD Thoracic Medical Oncologist Georgetown Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalAssistant Professor of MedicineGeorgetown University Medical CenterWashington, DC

Charles B. Simone, II, MD Medical Director, Maryland Proton Treatment CenterUniversity of Maryland Medical CenterAssociate Professor, Department of Radiation OncologyUniversity of Maryland School of MedicineBaltimore, MD

Thomas J. Watson, MD Regional Chief, MedStar Washington Integrated Surgery ServiceMedStar Georgetown University HospitalMedStar Washington Hospital CenterWashington, DC

Faculty

7:15 AM Registration and Breakfast

8:00 AM Welcome Remarks Deepa S. Subramaniam, MD, MSc

8:15 AM KEYNOTE ADDRESS: Navigating the Expanding Landscape in Thoracic Oncology

Giuseppe Giaccone, MD, PhD

SESSION I: DIAGNOSIS AND PREVENTION Moderator: Eric D. Anderson, MD

8:35 AM Case Presentation

8:45 AM The Latest Updates in CT Screening for Lung Cancer

Claudia I. Henschke, MD, PhD

9:05 AM Evolving Role of Liquid Tumor Biopsies Mark M. Awad, MD, PhD

9:25 AM Smoking Cessation Eric D. Anderson, MD

9:45 AM Panel Discussion Moderator: Eric D. Anderson, MD Panelists: M. Awad, C. Henschke

10:05 AM Break

SESSION II: LOCAL THERAPIES IN THE MANAGEMENT OF LUNG CANCER Moderator: Stephen V. Liu, MD

10:25 AM Case Presentation

10:35 AM Lung SABR: Evolving Indications in Early and Advanced Disease

Russell K. Hales, MD

10:55 AM The Role of Proton Beam Therapy in Thoracic Oncology

Charles B. Simone, II, MD

11:15 AM Controversies in the Surgical Management of Lung Cancer

Thomas J. Watson, MD

11:35 AM Panel Discussion Moderator: Stephen V. Liu, MD Panelists: R. Hales, C. Simone, T. Watson

11:55 AM Lunch

SESSION III: SYSTEMIC THERAPIES IN THEMANAGEMENT OF LUNG CANCER Moderator: Deepa S. Subramaniam, MD, MSc

12:45 PM Case Presentation

12:55 PM Clinical Update on Immune-Oncology in NSCLC

Stephen V. Liu, MD

1:15 PM Updates in EGFR-Mutant NSCLC Giuseppe Giaccone, MD, PhD

1:35 PM Management of ALK-Positive Lung Cancer Deepa S. Subramaniam, MD, MSc

1:55 PM Panel Discussion Moderator: Deepa S. Subramaniam, MD, MSc Panelists: G. Giaccone, S. Liu

SESSION IV: SPECIAL TOPICS IN THORACIC ONCOLOGY Moderator: Giuseppe Giaccone, MD, PhD

2:15 PM Case Presentation

2:25 PM Managing Toxicities Associated with Immunotherapeutics Geoffrey T. Gibney, MD

2:45 PM Management of Brain/Leptomeningeal Metastases in NSCLC Patients

Deepa S. Subramaniam, MD, MSc

3:05 PM Management of NSCLC Patients with Rare Mutations

Stephen V. Liu, MD

3:25 PM Panel Discussion Moderator: Giuseppe Giaccone, MD, PhD Panelists: G. Gibney, D. Subramaniam, S. Liu

3:45 PM Closing Remarks Giuseppe Giaccone, MD, PhD

3:55 PM Adjourn

Agenda

Registration Information Venue InformationREGISTRATION FEESPhysician.......................................................... $200 Resident/Fellow................................................. $35Advanced Practice Clinician............................. $100 Nurse................................................................ $100Allied Health Professional................................. $100

ONLINE REGISTRATION PREFERREDPlease visit our secure website at http://cme.medstarwashington.org/LungCancer for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at medstarCME@gmail.com or 202-780-1656.

CANCELLATION POLICY

Cancellations made in writing by September 28, 2016 will be subject to a 50% penalty. No refunds will be given after September 28, 2016. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, we will refund the registration fee, but are not responsible for any travel costs. Please call 202-780-1656 or email medstarcme@gmail.com if you any questions or need any additional information.

CAPITAL HILTON1001 16th Street, NWWashington, DC 20036202-393-1000

SPECIAL ASSISTANCE

MedStar Georgetown University Hospital and Georgetown Lombardi Comprehensive Cancer Center wish to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-780-1656 to notify us of your needs.